Company News »

InVivo Therapeutics’ Neuro-Spinal Scaffold Featured on NBC’s TODAY Show

Business Wire
Share on StockTwits
Published on

InVivo Therapeutics Holdings Corp. (NVIV) has announced that the company’s investigational Neuro-Spinal Scaffold was featured on NBC’s TODAY show this morning. Two patients enrolled in InVivo’s clinical study were featured along with Nicholas Theodore, M.D., Chief of Spinal Surgery, Barrow Neurosurgical Institute and Medical Director of the Neurological Trauma Program. Dr. Theodore, the Principal Investigator who implanted the first-ever Neuro-Spinal Scaffold into an acute spinal cord injury patient, made comments relating to the implantation procedure and provided his medical opinion on the technology.

Mark Perrin, InVivo Chief Executive Officer and Chairman, said, “I continue to be inspired by the enthusiasm and hope expressed by the two patients in our clinical study.”

For the full story, please visit TODAY’s site, here:
http://www.today.com/health/woman-finds-fairy-tale-love-returns-racing-after-paralysis-procedure-t24186

For discussion about conducting clinical trials in the age of social media, please visit “CEO’s Perspective” on the InVivo Therapeutics website: http://www.invivotherapeutics.com/about-invivo/ceo-perspective/

About the Neuro-Spinal Scaffold

Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and is currently being studied in an Investigational Device Exemption (IDE) pilot study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Share on StockTwits